31 results about "Lymphotoxin" patented technology

Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.

This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-α and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-α / β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.

Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.

The present invention relates to methods of treating and / or preventing obesity comprising the administration of an inhibitor of lymphotoxin, IL-22 and / or IL-23 to a subject having or at risk of developing obesity.

A therapeutically effective amount of an antibody for a compound selected from the group consisting of PTHrp, TGFα, IL-1α, IL-1β, IL-6, Lymphotoxin, TNF, PGE; 1,25 dihydroxy vitamin D3 and an antigenic fragment thereof used in the treatment of cancer metastasis to bone and cancer cell growth in bone as well as osteolysis and symptomatic sequelae thereof. An antibody immunoreactive with parathyroid hormone-related protein (PTHrp) is particularly preferred. Antibodies with human characteristics are included in the invention for application of the invention method to human subjects. Also, the antibody can be administered in an injectable is formulation in combination with a therapeutically effective amount of a bisphosphonate or pyrophosphate having the general structure formula wherein X is a linking moiety allowing for the interconnection of the phosphonate groups, and pharmaceutically acceptable salts, hydrates and partial hydrates thereof. The antibody and bisphosphonate act synergistically in the treatment of cancer metastases to bone and symptomatic sequelae thereof and particularly as regards bone resorption.

This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.

The object of the present invention is to determine inflammatory diseases such as myocardial infarction by identifying single nucleotide polymorphisms (SNPs) associated with myocardial infarction and utilizing these SNPs. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one gene polymorphism existing in at least one gene selected from the group consisting of a lymphotoxin-α (LT-α) gene, an I Kappa B-like (IKBL) gene, and a BAT1 gene; an oligonucleotide used in said method; a kit for diagnosing an inflammatory disease which comprises said oligonucleotide; and use thereof. The present invention further provides a method for treating an inflammatory disease; and a method for screening for a therapeutic agent for an inflammatory disease.

The present invention provides methods for restoring and increasing dendritic cell populations in a subject by modulation of the lymphotoxin-β receptor (LTβR) via LTβR agonists. The invention also provides methods for screening for agents capable of restoring or increasing dendritic cell populations. The invention further provides a method for the treatment of immunodeficiency by administration of an LTβR agonist.

This invention relates to compositions and methods useful for activating LT- beta receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin- alpha and multiple subunits of lymphotoxin- beta , which induce cytotoxic effects on tumor cells in the presence of lymphotoxin- beta receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin- beta receptor which act as lymphotoxin- beta receptor activating agents alone or in combination with other lymphotoxin- beta receptor activating agents either in the presence or absence of lymphotoxin- alpha / beta complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin- beta receptor antibodies either alone or in the presence of other lymphotoxin- beta receptor activating agents to potentiate tumor cell cytotoxicity.

The invention discloses a two-in-one far infrared lymphatic detoxification instrument. The two-in-one far infrared lymphatic detoxification instrument comprises airbag clothes capable of being worn on a human body and a main machine connected with the airbag clothes; a far infrared heating device for the human body is arranged on the airbag clothes and is connected with the main machine; the airbag clothes are provided with a plurality of airbags which are connected with the main machine; the main machine comprises a main control panel; the main control panel is connected with a far infrared control module; the far infrared control module is connected with the far infrared heating device; the main control panel is also connected with an air circuit control module; the air circuit control module is connected with an air pump; and the air pump is connected with the plurality of airbags through pipelines. The lymphatic detoxification instrument provided by the invention combines inflating airbag massaging and infrared heating functions, performs 360-degree whole body physical therapy massage on the whole body of a user, can control the temperature, and can perform lymphatic drainage in a targeted mode to promote circulation of the whole body blood circulation and lymphatic system of the user to remove lymphotoxin.

The object of the present invention is to determine inflammatory diseases such as myocardial infarction by identifying single nucleotide polymorphisms (SNPs) associated with myocardial infarction and utilizing these SNPs. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one gene polymorphism existing in at least one gene selected from the group consisting of a lymphotoxin-α (LT-α) gene, an I Kappa B-like (IKBL) gene, and a BAT1 gene; an oligonucleotide used in said method; a kit for diagnosing an inflammatory disease which comprises said oligonucleotide; and use thereof. The present invention further provides a method for treating an inflammatory disease; and a method for screening for a therapeutic agent for an inflammatory disease.

The invention discloses a new application of a lymphotoxin derivative LT008 (another name LTa-55) in preparation of drugs for preventing and treating a nuclear radiation injury, and particularly discloses a new application in preparation of drugs for treating radiation-induced acute and chronic tissue injuries or even severe organ dysfunction. Through a plurality of researches and drug screening tests, the results prove that the LT008 has a good effect in prevention and treatment of nuclear radiation diseases, especially radiation-induced acute and chronic tissue injuries or even severe organ dysfunction, and can be prepared into a new drug applied to the aspect.

A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.

The invention concentrates on the protein engineering and the pharmacy domain, that is, the application of the lymphotoxin in the domanial of tumor therapy. It concerned with the purpose of one kind of lymphotoxin, as the sensitization agents of chemotherapy that it cures the epidermis source tumour. There is distinct cruative effect generated by applying lymphotoxin with chemotheraphy together, with platinum medicament especially. The advantages are: the application of the lymphotoxin with chemotheraphy improving the cruative effect or declines the chemotheraphy medicine dosage with permission of cruative effect gurantee, which it can reduces the nagtive side effect from chemotherapy and improves the life quality of the patient.

The invention relates to a kit used for diagnosing the acute exacerbation period of chronic obstructive pulmonary disease. The kit comprises a cell factor and an enzyme labeled antibody thereof and is characterized in that the cell factor is interleukin 9, interleukin 18 binding protein A, C-C sequence ligand 28, a human skin T cell capture chemokine, a Beta cytokine, a monocyte chemoattractant protein-3, a monocyte chemoattractant protein-4, a lymphotoxin induced protein entering the T cell, a macrophage-derived chemokine, a human bone marrow suppression factor 1, a human macrophage stimulating protein, an osteopontin and a human thymus expressed chemokine. The invention firstly proposes that the cell factor can be used as a leading indicator for diagnosis of the acute exacerbation period of the chronic obstructive pulmonary disease.

The invention discloses a soluble TNF acceptor mutant, relating to tumor necrosis factor TNF acceptor derivant and its medical application. The amnio acid at 89th position of mutant is replaced and the ability of neutralizing cell toxicity of TNF alpha is retained, while ability of neutralizing LT is reduced by more than 10 times. The mutant can be used to treat over expressing disease of TNF alpha, because the affinity to lymphotoxin is reduced, the side effect caused by lymphotoxin neutralisation can be reduced, and the inhibitive effect to normal immunity function from medicine is aslo reduced.